These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 30042185)

  • 1. Evolution of genetic assessment for BRCA-associated gynaecologic malignancies: a Canadian multisociety roadmap.
    McCuaig JM; Stockley TL; Shaw P; Fung-Kee-Fung M; Altman AD; Bentley J; Bernardini MQ; Cormier B; Hirte H; Kieser K; MacMillan A; Meschino WS; Panabaker K; Perrier R; Provencher D; Schrader KA; Serfas K; Tomiak E; Wong N; Young SS; Gotlieb WH; Hoskins P; Kim RH;
    J Med Genet; 2018 Sep; 55(9):571-577. PubMed ID: 30042185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic testing in ovarian cancer - clinical impact and current practices.
    Knabben L; Imboden S; Mueller MD
    Horm Mol Biol Clin Investig; 2019 Oct; 41(3):. PubMed ID: 31577534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Finding all BRCA pathogenic mutation carriers: best practice models.
    Hoogerbrugge N; Jongmans MC
    Eur J Hum Genet; 2016 Sep; 24 Suppl 1(Suppl 1):S19-26. PubMed ID: 27514840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mainstreaming germline BRCA1/2 testing in non-mucinous epithelial ovarian cancer in the North West of England.
    Flaum N; Morgan RD; Burghel GJ; Bulman M; Clamp AR; Hasan J; Mitchell CL; Badea D; Moon S; Hogg M; Hadjiyiannakis D; Clancy T; Schlecht H; Woodward ER; Crosbie EJ; Edmondson RJ; Wallace AJ; Jayson GC; Lalloo FI; Harkness EF; Evans DGR
    Eur J Hum Genet; 2020 Nov; 28(11):1541-1547. PubMed ID: 32651552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives.
    Gori S; Barberis M; Bella MA; Buttitta F; Capoluongo E; Carrera P; Colombo N; Cortesi L; Genuardi M; Gion M; Guarneri V; Incorvaia L; La Verde N; Lorusso D; Marchetti A; Marchetti P; Normanno N; Pasini B; Pensabene M; Pignata S; Radice P; Ricevuto E; Sapino A; Tagliaferri P; Tassone P; Trevisiol C; Truini M; Varesco L; Russo A;
    Crit Rev Oncol Hematol; 2019 Aug; 140():67-72. PubMed ID: 31176273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Clinical Genetics Attendance at a Gynecologic Oncology Tumor Board on Referrals for Genetic Counseling and BRCA Mutation Testing.
    Cohen PA; Nichols CB; Schofield L; Van Der Werf S; Pachter N
    Int J Gynecol Cancer; 2016 Jun; 26(5):892-7. PubMed ID: 27051053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical practice guidelines for BRCA1 and BRCA2 genetic testing.
    Pujol P; Barberis M; Beer P; Friedman E; Piulats JM; Capoluongo ED; Garcia Foncillas J; Ray-Coquard I; Penault-Llorca F; Foulkes WD; Turnbull C; Hanson H; Narod S; Arun BK; Aapro MS; Mandel JL; Normanno N; Lambrechts D; Vergote I; Anahory M; Baertschi B; Baudry K; Bignon YJ; Bollet M; Corsini C; Cussenot O; De la Motte Rouge T; Duboys de Labarre M; Duchamp F; Duriez C; Fizazi K; Galibert V; Gladieff L; Gligorov J; Hammel P; Imbert-Bouteille M; Jacot W; Kogut-Kubiak T; Lamy PJ; Nambot S; Neuzillet Y; Olschwang S; Rebillard X; Rey JM; Rideau C; Spano JP; Thomas F; Treilleux I; Vandromme M; Vendrell J; Vintraud M; Zarca D; Hughes KS; Alés Martínez JE
    Eur J Cancer; 2021 Mar; 146():30-47. PubMed ID: 33578357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Referral patterns for genetic counselling of women diagnosed with tubo-ovarian or peritoneal high-grade serous carcinoma (HGSC) within the Auckland Gynaecological Oncology Centre.
    Burling MJ; Gamet K; Eva L; Tan AL
    Aust N Z J Obstet Gynaecol; 2019 Jun; 59(3):444-449. PubMed ID: 30883681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRCA mutation testing for ovarian cancer in the context of available targeted therapy: Survey and consensus of Hong Kong specialists.
    Kwong A; Cheng KD; Hsue CV; Hui SK; Leung CR; Leung KA; Ngan KR; Soong SI
    Asia Pac J Clin Oncol; 2019 Mar; 15 Suppl 2():20-31. PubMed ID: 30838787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of BRCA1 and BRCA2 large genomic rearrangements in Tunisian high risk breast/ovarian cancer families: Implications for genetic testing.
    Riahi A; Chabouni-Bouhamed H; Kharrat M
    Cancer Genet; 2017 Jan; 210():22-27. PubMed ID: 28212807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic counselling and testing of susceptibility genes for therapeutic decision-making in breast cancer-an European consensus statement and expert recommendations.
    Singer CF; Balmaña J; Bürki N; Delaloge S; Filieri ME; Gerdes AM; Grindedal EM; Han S; Johansson O; Kaufman B; Krajc M; Loman N; Olah E; Paluch-Shimon S; Plavetic ND; Pohlodek K; Rhiem K; Teixeira M; Evans DG
    Eur J Cancer; 2019 Jan; 106():54-60. PubMed ID: 30471648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two decades beyond BRCA1/2: Homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy.
    Walsh CS
    Gynecol Oncol; 2015 May; 137(2):343-50. PubMed ID: 25725131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Germline BRCA1/2 mutation testing is indicated in every patient with epithelial ovarian cancer: A systematic review.
    Arts-de Jong M; de Bock GH; van Asperen CJ; Mourits MJ; de Hullu JA; Kets CM
    Eur J Cancer; 2016 Jul; 61():137-45. PubMed ID: 27209246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention.
    Hanley GE; McAlpine JN; Miller D; Huntsman D; Schrader KA; Blake Gilks C; Mitchell G
    BMC Cancer; 2018 Mar; 18(1):254. PubMed ID: 29506471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of telephone genetic counselling to facilitate germline BRCA1/2 testing in women with high-grade serous ovarian cancer.
    Tutty E; Petelin L; McKinley J; Young MA; Meiser B; Rasmussen VM; Forbes Shepherd R; James PA; Forrest LE
    Eur J Hum Genet; 2019 Aug; 27(8):1186-1196. PubMed ID: 30962500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Germline BRCA testing is moving from cancer risk assessment to a predictive biomarker for targeting cancer therapeutics.
    Moreno L; Linossi C; Esteban I; Gadea N; Carrasco E; Bonache S; Gutiérrez-Enríquez S; Cruz C; Díez O; Balmaña J
    Clin Transl Oncol; 2016 Oct; 18(10):981-7. PubMed ID: 26742938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRCA1/2 testing: therapeutic implications for breast cancer management.
    Tung NM; Garber JE
    Br J Cancer; 2018 Jul; 119(2):141-152. PubMed ID: 29867226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Missed therapeutic and prevention opportunities in women with BRCA-mutated epithelial ovarian cancer and their families due to low referral rates for genetic counseling and BRCA testing: A review of the literature.
    Hoskins PJ; Gotlieb WH
    CA Cancer J Clin; 2017 Nov; 67(6):493-506. PubMed ID: 28881380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inadequate Rates of BRCA Testing with its Negative Consequences for Women with Epithelial Ovarian Cancer and their Families: an Overview of the Literature.
    Hoskins PJ
    Clin Oncol (R Coll Radiol); 2018 Aug; 30(8):472-483. PubMed ID: 29735311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status.
    Gadducci A; Guarneri V; Peccatori FA; Ronzino G; Scandurra G; Zamagni C; Zola P; Salutari V
    J Ovarian Res; 2019 Jan; 12(1):9. PubMed ID: 30691488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.